CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-targeting by antibody or from knockout mice

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 233-247

  Naor, David ^a,h   Nedvetzki, Shlomo ^a   Walmsley, Marita ^b   Yayon, Avner ^c   Turley, Eva A ^d   Golan, Ira ^a   Caspi, Dan ^e   Sebban, Lora Eshkar ^a   Zick, Yehiel ^f   Garin, Tali ^a   Karussis, Dimitrios ^g   Assayag Asherie, Nathalie ^a   Raz, Itamar ^g   Weiss, Lola ^g   Slavin, Shimon ^h   Golan, Itshak ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ProChon Biotech Ltd   (Israel)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Autoimmune diseases; CD168; CD44; Hyaluronan; Inflammation; Molecular redundancy

Indexed keywords

ANTIBODY; COLLAGEN; COMPLEMENTARY DNA; HERMES ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; CELL KILLING; CELL MIGRATION; CONFERENCE PAPER; GENE DELETION; GENE TECHNOLOGY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY CELL; INFLAMMATORY DISEASE; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; MOLECULAR MECHANICS; NONHUMAN; NONOBESE DIABETIC MOUSE;

MUS;

EID: 35748954360     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.025     Document Type: Conference Paper

References (40)

1. NAOR, D., S. NEDVETZKI, I. GOLAN, et al. 2002. Crit. Rev. Clin. Lab. Sci. 39: 527-579.
2. LESLEY, J., R. HYMAN & P.W. KINCADE. 1993. CD44 and its interaction with extracellular matrix. Adv. Immunol. 54: 271-335.
3. NAOR, D., R. VOGT-SIONOV & D. ISH-SHALOM. 1997. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 71: 241-319.
4. PONTA, H., L SHERMAN & P.A. HERRLICH. 2003. CD44: from adhesion molecules to signaling regulators. Nat. Rev. Mol. Cell. Biol. 4: 33-45.
5. VAN WEERING, D.H., P.D. BAAS & J.L. BOS. 1993. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl. 3: 100-106.
6. HOFMANN, M., W. RUDY, M. ZOLLER, et al. 1991. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res. 51: 5292-5297.
7. NEDVETZKI, S., I. GOLAN, N. ASSAYAG, et al. 2003. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J. Clin. Invest. 111: 1211-1220.
8. GOLAN, I., S. NEDVETZKI, I. GOLAN, et al. 2007. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody. J. Autoimmun. 28: 99-113.
9. CHOY, E.H. & G.S. PANAYI. 2001. Cytokine pathway and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
10. MOHLER, K.M., D.S. TORRANCE, C.A. SMITH, et al. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151: 1548-1561.
11. ELLIOTT, M.J., R.N. MAINI, M. FELDMANN, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
12. NEDVETZKI, S., M. WALMSLEY, E. ALPERT, et al. 1999. CD44 involvement in experimental collagen-induced arthritis (CIA). J. Autoimmun. 13: 39-47.
13. NEDVETZKI, S., E. GONEN, N. ASSAYAG, et al. 2004. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc. Natl. Acad. Sci. USA 101: 18081-18086.
14. MIKECZ, K., F.R. BRENNAN, J.H. KIM, et al. 1995. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat. Med. 1: 558-563.
15. VERDRENGH, M., R. HOLMDAHL & A. TARKOWSKI. 1995. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. Scand. J. Immunol. 42: 353-358.
16. ZEIDLER, A., R. BRAUER, K. THOSS, et al. 1995. Therapeutic effects of antibodies against adhesion molecules in murine collagen type II-induced arthritis. Autoimmunity 21: 245-252.
17. NAOR, D. & S. NEDVETZKI. 2003. CD44 in rheumatoid arthritis. Arthritis Res. Ther. 5: 105-115.
18. SPRINGER, T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314.
19. DEGRENDELE, H.C., P. ESTESS & M.H. SIEGELMAN. 1997. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278: 672-675.
20. WALLACH-DAYAN, S.B., V. GRABOVSKY, J. MOLL, et al. 2001. CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J. Cell Sci. 114: 3463-3477.
21. SCHMITS, R., J. FILMUS, N. GERWIN, et al. 1997. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90: 2217-2233.
22. TAYLOR, K.R. & R.L. GALLO. 2006. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 20: 9-22.
23. TURLEY, E.A., P.W. NOBLE & L.Y. BOURGUIGNON. 2002. Signaling properties of hyaluronan receptors. J Biol Chem. 277: 4589-4592.
24. HADARI, Y.R., K. PAZ, R. DEKEL, et al. 1995. Galectin-8: a new rat lectin, related to galectin-4. J. Biol. Chem. 270: 3447-3453.
25. BIDON, N., F. BRICHORY, P. BOURGUET, et al. 2001. Galectin-8: a complex subfamily of galectins [review]. Int. J. Mol. Med. 8: 245-250.
26. HADARI, Y.R., R. ARBEL-GOREN, Y. LEVY, et al. 2000. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J. Cell Sci. 113: 2385-2397.
27. LEVY, Y., R. ARBEL-GOREN, Y.R. HADARI, et al. 2001. Galectin-8 functions as a matricellular modulator of cell adhesion. J. Biol. Chem. 276: 31285-31295.
28. ZICK, Y., M. EISENSTEIN, R.A. GOREN, et al. 2004. Role of galectin-8 as a mediator of cell adhesion and cell growth. Glycoconj. J. 19: 517-526.
29. ARBEL-GOREN, R., Y. LEVY, D. RONEN, et al. 2005. Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8. J. Biol. Chem. 280: 19105-19114.
30. ZAMVIL, S.S. & L. STEINMAN. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8: 579-621.
31. MARTIN, R., H.F. MCFARLAND & D.E. MCFARLIN. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10: 153-187.
32. SWANBORG, R.H. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77: 4-13.
33. BROCKE, S., C. PIERCY, L. STEINMAN, et al. 1999. Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA 96: 6896-6901.
34. GARIN, T., A. RUBINSTEIN, N. GRIGORIADIS, et al. 2007. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J. Neurol. Sci. In press.
35. ATKINSON, M.A. & G.S. EISENBARTH. 2001. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
36. HEROLD, K.C., W. HAGOPIAN, J.A. AUGER, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
37. WEISS, L., S. SLAVIN, S. REICH, et al. 2000. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. USA 97: 285-290.
38. TEDER, P., R.W. VANDIVIER, D. JIANG, et al. 2002. Resolution of lung inflammation by CD44. Science 296: 155-158.
39. HAYER, S., G. STEINER, B. GORTZ, et al. 2005. CD44 is a determinant of inflammatory bone loss. J. Exp. Med. 201: 903-914.
40. ROUSCHOP, K.M., N. CLAESSEN, S.T. PALS, et al. 2006. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-β1-induced apoptosis. J. Am. Soc. Nephrol. 17: 746-753.